HOME >> MEDICINE >> NEWS
Second NIAID SARS vaccine candidate helps mice fend off SARS

An experimental vaccine based on a critical piece of the SARS virus protects mice from SARS infection, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found. When exposed to the SARS virus, immunized mice produced SARS-specific antibodies, and virus replication was nearly eliminated.

The new report, to be published this week in the Proceedings of the National Academy of Sciences online, is the second from NIAID in recent weeks describing a promising SARS vaccine candidate.

"We now have two candidate vaccines, based on two distinct technologies, shown to be effective against SARS infection in mice," says NIAID Director Anthony S. Fauci, M.D. "The animal model employed in both studies was developed by NIAID researchers as well. By taking various approaches to vaccine development, we are making significant research progress against a disease that was unknown little more than a year ago."

SARS is caused by a coronavirus, a family of viruses so named because spiky proteins protrude from the virus's surface, giving the microbe a crown-like appearance. The newly described vaccine is based on the spike (S) protein. Because the virus initiates infection by attaching to and entering cells using its S protein, a vaccine based on this protein should closely mimic natural infection, notes senior author, Bernard Moss, M.D., Ph.D.

Investigators inserted the gene encoding the S protein into a virus called modified vaccinia Ankara (MVA). Neither MVA nor the solitary gene from the SARS virus can cause disease. Instead, MVA simply ferries the SARS gene into the body. First developed as a vaccine against smallpox, MVA has an excellent safety record in humans, says Dr. Moss, and it efficiently stimulates both the antibody and cellular arms of the immune system.

Dr. Moss and his colleagues collaborated in this research with fellow NIAID scientist Kanta Subbarao,
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
19-Apr-2004


Page: 1 2

Related medicine news :

1. Secondhand smoke linked to cervical cancer
2. Secondhand smoke impairs lung function in women
3. Second stage of HIV vaccine trial begins in London and Oxford, UK
4. Second patient with multiple sclerosis undergoes groundbreaking surgery at Yale
5. Cholesterol Carriers Better Predictors Than Cholesterol For Second Heart Attack
6. Second Annual AIDS Vaccine Day Honors Volunteers Nationwide
7. Patients Treated Successfully For Hodgkins Disease Are At 9 Times The Risk For Developing Second Cancer
8. Cedars-Sinai Medical Centers Prenatal Program Pushes the Frontiers of Diagnosis From the Second Trimester Into the First
9. AAPS Sponsors Second Frontier Symposium
10. Drug Combination Including New "Super Aspirin" Drug Cuts Risk Of Death Or Second Heart Attack
11. Drugs Effect On Chromosomes May Explain Second Cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
Cached News: